Lisa Feldman

Dr. Lisa Feldman

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LFLisa Feldman
Lisa Feldman
Glioblastoma (GBM) tumors are the most aggressive primary brain tumors in adults that, despite maximum treatment, carry a dismal prognosis. GBM tumors exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells and creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring the proliferation of immunosuppressive cells and inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, and CAR-T cell therapy, represent promising avenues for GBM treatment. However, challenges such as tumor heterogeneity, immunosuppressive TME, and BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, including combination therapies and targeting hypoxia, are actively being explored to improve outcomes for GBM patients. Targeting hypoxia in combination with immunotherapy represents a potential strategy to enhance treatment efficacy.

11 February 2021 in Neurosurgery
Verified
Journal Article
Closed access
LFLisa Feldman
Lisa Feldman
CBChristine Brown
Christine Brown
BBBehnam Badie
Behnam Badie
Glioblastoma multiforme (GBM) are the most common and among the deadliest brain tumors in adults. Current mainstay treatments are insufficient to treat this tumor, and therefore, more effective therapies are desperately needed. Immunotherapy, which takes advantage of the body's natural defense mechanism, is an exciting emerging field in neuro-oncology. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells provides a treatment strategy based on using patients’ own selected and genetically engineered cells that target tumor-associated antigens. These cells are harvested from patients, modified to target specific proteins expressed by the tumor, and re-introduced into the patient with the goal of destroying tumor cells. Here, we review the history of CAR T-cell therapy, and describe the characteristics of various generations of CAR T therapies, and the challenges inherent to treatment of GBM. Finally, we describe recent and current CAR T clinical trials designed to combat GBM.

19 October 2021 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
LFLisa Feldman
Lisa Feldman
CBChristine Brown
Christine Brown
BBBehnam Badie
Behnam Badie

19 February 2026 in Molecular Therapy Oncology
Verified
Journal Article
Open access
YWYujun Wang
Yujun Wang
YJYongsheng Jia
Yongsheng Jia
YYYate-Ching Yuan
Yate-Ching Yuan
GLGang Li
Gang Li
JWJinhui Wang
Jinhui Wang
LFLisa Feldman
Lisa Feldman
Glioblastoma (GBM) is an aggressive primary brain tumor that, partly due to its hypoxic tumor microenvironment (TME), is extremely difficult to treat. In our study, RNA sequencing and quantitative reverse-transcription PCR (qRT-PCR) analysis identified differential expression of chromobox 6 (CBX6) and carbonic anhydrase 9 (CA9) in GBM cells under hypoxic conditions. Downregulation of CBX6, a member of the Polycomb group proteins, occurs under hypoxic conditions and is associated with higher-grade tumors and worse patient survival. Here, we show that silencing CBX6 in GBM cells promotes proliferation, migration, and invasion, while its overexpression yields the opposite effects, indicating its role as a negative regulator of tumor aggressiveness. CA9, upregulated by hypoxia, contributes to an acidic environment supporting tumor growth, a more aggressive GBM phenotype, and treatment resistance. Our qRT-PCR and short hairpin RNA (shRNA)-mediated knockdown experiments demonstrate an inverse relationship between CBX6 and CA9 expression across various human and murine GBM cell lines. Chromatin immunoprecipitation (ChIP) assays with multiple primers confirmed that CBX6 binds to the CA9 promotor, suggesting that CBX6 regulates CA9 expression. Our findings highlight CBX6 and CA9 as potential therapeutic targets, offering insights into GBM biology and the response to hypoxia.

14 November 2024
Verified
Book Chapter
Closed access
PDF file
CCClara Chen
Clara Chen
CBCynthia Basulto
Cynthia Basulto
TNTalha Nazir
Talha Nazir
NHNamath Hussain
Namath Hussain
Babak KatebBabak Kateb
Babak Kateb
LFLisa Feldman
Lisa Feldman

31 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YWYujun Wang
Yujun Wang
RURyan Urak
Ryan Urak
CCClara Jinnette Chen
Clara Jinnette Chen
MSMartha Salas
Martha Salas
CBChristine E Brown
Christine E Brown
LFLisa Feldman
Lisa Feldman
Background/Objectives: Interleukin-13 receptor alpha 2 (IL13Rα2), expressed in more than 75% of glioblastomas (GBM), is a promising chimeric antigen receptor (CAR) T cell target. We investigated how microenvironmental stresses regulate IL13Rα2 expression and whether extracellular vesicle (EV)-mediated antigen transfer modulates CAR T cell killing. Methods: Patient-derived brain tumor and other GBM cell lines were exposed to hypoxia, desferrioxamine (DFO), or reduced fetal bovine serum (FBS). Western blotting assessed IL13Rα2 expression and recovery following reoxygenation. Fluorescence imaging evaluated EV interactions with recipient cells, and cytotoxicity assays assessed CAR T cell killing. Results: Hypoxia and DFO markedly suppressed IL13Rα2 expression. Exposure to 1% oxygen for 48 h reduced protein levels by 40–70%; expression recovered to near-baseline levels within 48 h of reoxygenation. Reduced FBS concentrations for 48 h also decreased IL13Rα2 expression compared with 10% FBS. Findings suggested potential contributions from ubiquitin-dependent degradation and transcriptional mechanisms. IL13Rα2-expressing EVs showed a slight increase under hypoxia. Fluorescence imaging confirmed that IL13Rα2-containing EVs attached to or entered recipient GBM cells within hours. EV-mediated antigen transfer increased CAR T cell killing by 3–5%. Conclusions: Hypoxia and nutrient availability dynamically regulate IL13Rα2 expression, while EVs can transfer the antigen between GBM cells and modestly enhance CAR T cell killing. These findings highlight reversible antigen modulation and EV-mediated antigen redistribution as mechanisms that could inform strategies to overcome antigen escape and improve immune targeting in GBM.